Exscientia, a company focusing on AI-powered drug discovery, has raised $225M in a Series D led by SoftBank Group. It also secured a $300M convertible note from SoftBank.
How’s the company performing?
- Oxford-based Exscientia uses AI to precision engineer new drugs. The company has pushed 2 drugs into clinical trials to date and has another 20 active programs in the pipeline.
- In January 2020, Exscientia and partner Dainippon Pharma announced that their first AI-designed drug candidate, a treatment for obsessive-compulsive disorder, had advanced into clinical trials. The process took just a year, compared to the average timeline of 4.5 years.
- Exscientia currently has over 100 employees across 20 countries and recently expanded into the US, in Miami and Boston.
- It has raised more than $672M to date. In March 2021, Exscientia raised a $40M Series C-II with participation from BlackRock.
Want the full post? Become a CB Insights customer.
If you’re already a customer, log in here.
The post Softbank-Backed Exscientia Raises $225M To Enhance Its Autonomous Drug Design Platform appeared first on CB Insights Research.